Basilea's Business Strategy Emboldened By $500m Pfizer Deal
Executive Summary
Swiss company Basilea has attracted Pfizer as a European partner for its antifungal Cresimba and plans to strengthen its development pipeline with licensed-in products and further collaborations.
You may also be interested in...
Basilea-Pfizer’s Cresemba Heads For Indian Debut
Basilea’s Cresemba appears on course to a debut in India and partner Pfizer expects the novel antifungal to bolster its existing portfolio in the segment. Pricing of the product will be keenly watched.
Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy
Day three at the BIO International Convention included an off-site visit to Lilly's newly expanded R&D site as well as conversations with Sigilon about the $23m Series A venture funding round it announced that morning and with CytomX about its dealmaking strategy.